Indusatumab vedotin

Indusatumab vedotin (MLN-0264) is an antibody-drug conjugate that is under development for the treatment of pancreatic cancer[1] and other gastrointestinal cancers.[2] It consists of a monoclonal antibody (indusatumab) that targets the enzyme guanylate cyclase 2C which is present in some cancers, linked to an average of three to four molecules of the chemotherapeutic agent monomethyl auristatin E (MMAE).[3]

Indusatumab vedotin
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetGuanylate cyclase 2C
Clinical data
Other namesMLN-0264, 5F9vcMMAE
Routes of
administration		Intravenous
ATC code
  • none
Legal status
Legal status
  • Experimental
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Molar mass~150 kg/mol

It was in Phase II clinical trials as of February 2016. The trials were terminated in 2017 because of insufficient efficacy.[1][2][4]

References
  1. Clinical trial number NCT02202785 for "A Study of MLN0264 in Patients With Pancreatic Cancer" at ClinicalTrials.gov
  2. Clinical trial number NCT02202759 for "A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction" at ClinicalTrials.gov
  3. "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 74" (PDF). WHO Drug Information. 29 (3): 402–3. 2015.
  4. Almhanna K, Wright D, Mercade TM, et al. (2017). "A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C". Invest New Drugs. 35 (5): 634–641. doi:10.1007/s10637-017-0473-9. PMID 28527133. S2CID 3653513.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.